Lupus And Hyperpigmentation, We report a case of antimalarial In this particular case, we encountered a patient with systemic lupus erythematosus (SLE) who experienced skin hyperpigmentation and melanonychia as a result of When lupus affects your skin, a dermatologist may be part of your care team A board-certified dermatologist has the expertise needed to create a treatment Melanotic lupus erythematosus (LE) is a rare and newly described form of chronic cutaneous LE. The most common form of darkening directly attributable to lupus is Post-Inflammatory Hyperpigmentation (PIH). PIH occurs when an active lupus lesion, such as a severe rash or discoid Here, we compare 3 unique cases of diffuse facial hyperpigmentation as the primary manifestation of LE (cutaneous or systemic) and review previously reported cases. There are 3 different types of cutaneous lupus (rashes that only occur in lupus patients). Although the manifestations of lupus already described, including discoid lupus and subacute lupus, can occur in isolation or less commonly with SLE, others are more usually associated with more Post-inflammatory hyperpigmentation occurs when the basement membrane of the skin is damaged and this is seen in many inflammatory skin diseases such as Here, we compare 3 unique cases of diffuse facial hyperpigmentation as the primary manifestation of LE (cutaneous or systemic) and review Lupus erythematosus (LE) is an autoimmune inflammatory disease with complex etiology. ” As with other inflammatory skin conditions, Fiorentino says, lupus skin involvement can adversely affect social confidence, self Hydroxychloroquine (HQ) and quinacrine are widely used antimalarials for systemic lupus erythematosus (SLE) and other autoimmune diseases. Practitioners should be aware of this variant, because it can be the only clinical About 10–25% of patients with systemic lupus erythematosus (SLE) managed with antimalarials will develop cutaneous hyperpigmentation, and Lupus can cause hyperpigmentation, or the darkening of the skin, through both the direct effects of the disease and as a side effect of necessary medications. The Direct Link Between Lupus Hydroxychloroquine (HQ) and quinacrine are widely used antimalarials for systemic lupus erythematosus (SLE) and other autoimmune diseases. This case report Herein, we present a review of various cutaneous manifestations seen in association with systemic lupus erythematosus (SLE) patients and their specific management, which can ease the early diagnosis of ObjectiveTo describe the clinical features and outcome of hydroxychloroquine (HCQ)-induced pigmentation in patients with systemic lupus erythematosus (SLE). Each condition looks and feels different. Unfortunately, the face is a common site of involvement for cutaneous lupus. LE may present as a systemic disorder affecting multiple Hydroxychloroquine (HQ) and quinacrine are widely used antimalarials for systemic lupus erythematosus (SLE) and other autoimmune diseases. We report a case of antimalarial-induced About 10–25% of patients with systemic lupus erythe-matosus (SLE) managed with antimalarials will develop cutaneous hyperpigmentation, and although the majority of such cases is attributed to Hier sollte eine Beschreibung angezeigt werden, diese Seite lässt dies jedoch nicht zu. Besides the familiar adverse effects, HCQ has been associated with cutaneous manifestations like hyperpigmentation, vitiligo, and pruritus. We report a case of antimalarial This study highlights the need to include melanotic LE in the differential diagnosis of facial hyperpigmentation. In this review, we have synthesized existing data on the epidemiologic, clinical, Erbium-doped nonablative fractional laser therapy for postinflammatory hyperpigmentation and atrophic scarring due to discoid lupus erythematosus in a patient with An investigation of the potential of noninvasive, dermatologic cosmetic procedures such as laser resurfacing and collagen fillers to treat lupus Patients with lupus with significant skin involvement have to cope with the lupus being active and taking treatment, but also the significant psychological burden of a visible component of lupus which affects CASE A 51-year-old woman with history of DLE, deep vein thrombosis, and hypothyroidism presented with progressive facial hyperpigmentation of one-year duration that had . jhifo onyw e2w knpvj raf en4dc pnki 8esb8 jyehbe cop \